PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.

Abstract To date, it has not been well characterized whether sunitinib is effective in elderly patients with metastatic renal cell carcinoma (mRCC). The objective of this study was to investigate the impact of age on clinical outcomes of mRCC patients receiving sunitinib.
PMID
Related Publications

Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.

The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.

Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.

Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.

Authors

Mayor MeshTerms

Aging

Keywords

Metastatic renal cell carcinoma

age

efficacy

safety

sunitinib

Journal Title anticancer research
Publication Year Start




PMID- 29848715
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20180611
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 6
DP  - 2018 Jun
TI  - Significance of Age in Japanese Patients Receiving Sunitinib as First-line
      Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of
      Efficacy and Safety between Patients Aged &lt;75 and &gt;/=75 Years.
PG  - 3593-3599
LID - 10.21873/anticanres.12633 [doi]
AB  - BACKGROUND/AIM: To date, it has not been well characterized whether sunitinib is 
      effective in elderly patients with metastatic renal cell carcinoma (mRCC). The
      objective of this study was to investigate the impact of age on clinical outcomes
      of mRCC patients receiving sunitinib. PATIENTS AND METHODS: The efficacy and
      safety of first-line sunitinib in 154 consecutive mRCC patients were
      retrospectively compared between patients aged &lt;75 (n=125) and &gt;/=75 (n=29)
      years. RESULTS: There were no significant differences in the major
      clinicopathological characteristics between younger and older patients; however, 
      the reduction of the initial dose of sunitinib was significantly more frequent in
      older than younger patients. No significant difference in response rate, clinical
      benefit rate or proportion of patients going on to receive second-line therapy
      was noted between these two groups. Furthermore, there was no significant
      difference in progression-free survival (PFS) or overall survival (OS) between
      the two groups, and no significant impact of age on PFS or OS was documented by
      the Cox proportional hazards regression analyses. Of several adverse events, only
      anemia and fatigue were significantly more frequently observed in older than
      younger patients. Although there was no significant difference in the incidence
      of dose reduction or discontinuation of sunitinib between the two groups, the
      interruption of sunitinib was more frequently required in older than younger
      patients. CONCLUSION: These findings suggest that advanced age alone should not
      be regarded as a contraindication to the introduction of sunitinib as first-line 
      systemic therapy for mRCC patients.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Miyake, Hideaki
AU  - Miyake H
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan 
      [email protected]
FAU - Aki, Ryota
AU  - Aki R
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Matsushita, Yuto
AU  - Matsushita Y
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Tamura, Keita
AU  - Tamura K
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Motoyama, Daisuke
AU  - Motoyama D
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Ito, Toshiki
AU  - Ito T
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Sugiyama, Takayuki
AU  - Sugiyama T
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
FAU - Otsuka, Atsushi
AU  - Otsuka A
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - V99T50803M (sunitinib)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aging
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Asian Continental Ancestry Group
MH  - Carcinoma, Renal Cell/*drug therapy/ethnology/pathology
MH  - Disease-Free Survival
MH  - Fatigue/chemically induced
MH  - Female
MH  - Humans
MH  - Indoles/adverse effects/*therapeutic use
MH  - Japan
MH  - Kidney Neoplasms/*drug therapy/ethnology/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Pyrroles/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Thrombocytopenia/chemically induced
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Metastatic renal cell carcinoma
OT  - age
OT  - efficacy
OT  - safety
OT  - sunitinib
EDAT- 2018/06/01 06:00
MHDA- 2018/06/12 06:00
CRDT- 2018/06/01 06:00
PHST- 2018/03/29 00:00 [received]
PHST- 2018/04/29 00:00 [revised]
PHST- 2018/05/02 00:00 [accepted]
PHST- 2018/06/01 06:00 [entrez]
PHST- 2018/06/01 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
AID - 38/6/3593 [pii]
AID - 10.21873/anticanres.12633 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jun;38(6):3593-3599. doi: 10.21873/anticanres.12633.